MammaPrint test reportMammaPrint provides a clear low risk or high risk result to better predict breast cancer recurrence
MammaPrint High RiskA high risk result means that a patient has a statistically significant (11.7%) chance that her cancer will recur within 5 years1 View high risk report
MammaPrint Low RiskA low risk result means that a patient has a statistically significant (1.3%) chance that her cancer will recur within 5 years1 View low risk report
Recommended by expert medical guidelines
MammaPrint is included in numerous clinical practice guidelines developed by world-recognized cancer care organizations. Clinical guidelines are evidence-based recommendations for healthcare professionals involved in the management of patients.
Guidelines aim to improve the quality of care and services based on the most up to date peer-reviewed evidence. For example, MammaPrint is the only test of its kind endorsed by the American Society of Clinical Oncology for lymph node-positive patients.
Also included in the National Comprehensive Cancer Network® (NCCN®).
70-Gene Assay (MammaPrint) has a Category 1 recommendation from the National Comprehensive Cancer Network® (NCCN®). Category 1 is based upon high-level evidence; there is uniform NCCN consensus that intervention is appropriate. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © 2019 National Comprehensive Cancer Network, Inc 2019. All rights reserved. To view the most recent and complete version of the guidelines, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
70-gene Assay (MammaPrint) is the only genomic assay with FDA clearance and Level 1 evidence by the American Society of Clinical Oncology (ASCO).
Where to next?
I kept thinking maybe I’d made the wrong decision, maybe I should have had a mastectomy. MammaPrint allowed me to calm down, refer back to my results, and return to the faith I had in my treatment. — Mary, a breast cancer survivor